Australia markets closed

    -57.60 (-0.82%)
  • ASX 200

    -49.90 (-0.74%)

    -0.0036 (-0.47%)
  • OIL

    +2.45 (+3.84%)
  • GOLD

    -2.50 (-0.15%)

    +1,710.42 (+2.76%)
  • CMC Crypto 200

    +39.75 (+4.21%)

    +0.0003 (+0.05%)

    -0.0018 (-0.17%)
  • NZX 50

    -44.25 (-0.36%)

    +204.51 (+1.64%)
  • FTSE

    -20.36 (-0.31%)
  • Dow Jones

    +572.16 (+1.85%)
  • DAX

    -135.65 (-0.97%)
  • Hang Seng

    -138.51 (-0.47%)
  • NIKKEI 225

    -65.78 (-0.23%)

Global Epileptic Seizures Treatment Market to Surpass US$ 4.5 Billion by 2027, Says Coherent Market Insights (CMI)

·4-min read

According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).

Key Trends and Analysis:

Manufacturers in the epileptic seizures treatment market are continuously focusing on investing in R&D of new drugs to meet demand for effective medications for treating epilepsy, which is expected to drive growth of the epileptic seizures treatment market over the forecast period. For instance, in May 2016, Marinus Pharmaceuticals developed Ganaxolone, which is a CNS-selective GABAA modulator in three different dose forms (capsule, IV, and liquid) for the treatment of children with rare genetic epilepsies.

The increasing collaborations, partnerships, and agreements between the major players for developing more advanced drugs for epileptic seizures treatment is expected to accelerate the epileptic seizures treatment market growth. For instance, in October 2020, Ono Pharmaceutical Co., Ltd. entered into an exclusive license agreement with SK Biopharmaceuticals, Co., Ltd. for the development and commercialization of cenobamate, SKBP’s antiepileptic drug, in Japan.

Buy-Now this Research Report @

Furthermore, distribution and license agreements within the subsidiaries and parent companies are expected to boost the sales of the anti-epileptic drugs, which will boost the epileptic seizures treatment market growth. For instance, in June 2016, Sun Pharma Advanced Research Company (SPARC) and its parent company Sun Pharma entered into a licensing arrangement for its Elepsia tablets, used in the treatment of epilepsy, in the U.S. market for an up-front payment of US$ 10 million. As per the agreement, SPARC gave license of Elepsia XRTM (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma in the U.S. market. SPARC received an up-front payment of US$ 10 million from Sun Pharma.

Key Market Takeaways:

The global epileptic seizures treatment market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), owing to the increasing product approvals and launches for epileptic seizures treatment. For instance, in April 2020, J B Chemicals & Pharmaceuticals received U.S. FDA approval for the company's abbreviated new drug application (ANDA) for Carbamazepine extended release tablets USP 100 mg, 200 mg, and 400 mg indicated for treatment of epilepsy and Trigeminal Neuralgia. The product is a generic version of Tegretol XR tablet in the same strength of Novartis Pharmaceuticals Corp.

Key players in the North America epileptic seizures treatment market are focused on clinical trials for development of new drugs, which is expected to drive growth of the market during the forecast period. For instance, Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, reported positive top-line results from its third Phase 3 study of FINTEPLA (fenfluramine), oral solution for the treatment of seizures associated with Dravet syndrome. The study validates the substantial impact of FINTEPLA on convulsive seizure reduction previously demonstrated in two earlier Phase 3 trials in patients with this severe, rare, and often debilitating form of infant-onset epilepsy.

Competitive Landscape:

Key players operating in the global epileptic seizures treatment market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.

Request Sample Copy of this Report @

Market Segmentation:

  • By Drug Type:

    • First Generation

    • Second Generation

    • Third Generation

  • By Seizure Type:

    • Partial Seizures

    • Generalized Seizures

    • Unclassified Seizures

  • By Route of Administration:

    • Oral/Buccal

    • Nasal

    • Rectal

    • Parenteral

  • By Distribution Channel:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • By Region:

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • Italy

      • Spain

      • France

      • Russia

      • Rest of Europe

    • Asia Pacific

      • Australia

      • India

      • China

      • Japan

      • ASEAN

      • South Korea

      • Rest of Asia Pacific

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Rest of Latin America

    • Middle East

      • GCC

      • Israel

      • Rest of Middle East

    • Africa

      • South Africa

      • Central Africa

      • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on


Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Follow Us: LinkedIn | Twitter